Based in Goa, Tulip provides in-vitro diagnostic reagents, kits and instruments for diagnostic labs, government and private healthcare facilities in the country.

The company produces products for the prevention, screening and diagnosis of infectious diseases such as malaria, HIV and hepatitis.

With around 1,200 employees, Tulip operates two manufacturing facilities in Goa and Uttarakhand. It also has 12 branch offices that will provide services for around 30,000 customers and 1,000 distributors in India.

The deal is expected to complete in the first quarter of this year.

PerkinElmer diagnostics president and senior vice president Prahlad Singh said: As we continue to build out our Diagnostics business on a global scale, this acquisition further positions PerkinElmer for long-term growth in emerging market diagnostics, an attractive end market and key area of focus for us.

"We are committed to expanding our infectious disease screening menu and capabilities, and Tulip's product portfolio, channel access, and broad footprint provide the key enablers to help accelerate our growth in this important market."

In January 2016, PerkinElmer acquired Sweden-based Vanadis Diagnostics, which is engaged in the development of novel solution for non-invasive prenatal testing (NIPT) based on digital analysis of cell-free DNA.

Through its range of instruments, reagents and assay platforms and software offerings, PerkinElmer provides diagnostic products for reproductive health, infectious disease screening and genomics offerings for oncology and other molecular tests.

Image: Tulip Diagnostics produces in-vitro diagnostic reagents, kits and instruments. Photo: courtesy of Suwit Ritjaroon /